Add BrightSurf on Google Email

Wash U Medicine Cancer study professional recognized with Clinical Research Integrity Award by Alliance for Clinical Trials in Oncology

Jennifer Frederick, an oncology clinical trial organizer at Wash U Medicine, received the 2026 Alliance Clinical Research Professionals Research Integrity Service Award for her dedication to helping cancer patients access clinical trials. Her work ensures that trials run smoothly and safely, with a focus on patient advocacy and compass...

Conducting traditional Chinese medicine trials that achieve global credibility

Traditional Chinese medicine trials must meet international standards to generate credible evidence, including clinical questions, experienced trialists, and adequate sample sizes. The trials should be conducted in multiple hospital locations, including Western centers, to build confidence among Western doctors and patients.

SourceSciOpen·JournalEvidence-Based Chinese Medicine and Technology Assessment·DateNov 6, 2026

Integrated health service delivery through medical mobile units helped to reduce deaths among individuals at risk for HIV who also inject drugs

A clinical trial funded by the NIH found that integrated HIV and substance use disorder services delivered through mobile medical units reduced all-cause deaths by 71% compared to community-based services. The trial showed no difference in PrEP and MOUD use, highlighting the need for long-acting PrEP formulations in this population.

SourceNIH/Office of the Director·JournalJAMA Psychiatry·DateNov 4, 2026

Interleukin-33 alleviates the immunosuppressive tumor microenvironment and enhances anti–PD-L1 immunotherapy efficacy in hepatocellular carcinoma

This study demonstrates that interleukin-33 alleviates the immunosuppressive tumor microenvironment in hepatocellular carcinoma, activating the STING/IRF axis and increasing functional CD8⁺ T cells. Combining IL-33 with anti-PD-L1 therapy synergistically reduces tumor burden and boosts anti-tumor immunity in vivo.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeExperimental study·DateOct 30, 2026

Chinese Medical Journal article review explores hepatitis B surface antigen clearance rate in chronic hepatitis B virus infection treated with pegylated interferon-α

Researchers found that pegylated interferon-α therapy significantly increases hepatitis B surface antigen clearance in different chronic hepatitis B infection groups, including nucleos(t)ide analogs-experienced patients and children. The therapy achieves high clearance rates in these groups, particularly in those with high baseline lev...

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·DateOct 30, 2026

Chinese Neurosurgical Journal reports early neurological outcomes after awake craniotomy

A retrospective study of 30 patients undergoing awake craniotomy found that 30% experienced new or worsened neurological dysfunction within 48–72 hours after surgery. Early functional and cognitive score reductions were common, while new-onset aphasia occurred in 10% of patients. The findings highlight the importance of interpreting ea...

SourceChinese Neurosurgical Journal·JournalChinese Neurosurgical Journal·TypeObservational study·DateOct 26, 2026

Swim Across America-funded cancer research leads to landmark FDA approval of immunotherapy for rectal cancer

A groundbreaking immunotherapy treatment for rectal cancer has received FDA approval, offering patients with locally advanced rectal cancer the possibility of eliminating their cancer without chemotherapy, radiation, or surgery. The treatment, developed through pioneering research at Memorial Sloan Kettering Cancer Center, has shown a ...

SourceSwim Across America·TypeRandomized controlled/clinical trial·DateOct 22, 2026

Three-week radiation course a safe option for breast cancer patients undergoing reconstruction, Alliance trial shows

A new trial shows that a shorter three-week radiation course is as safe and effective as the standard five-week treatment for women undergoing breast reconstruction. The RT CHARM trial found no increase in complications or effects on reconstruction efforts.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateOct 21, 2026

Recompensation may represent a new treatment-related state in cirrhosis

Researchers propose recognizing recompensation as a distinct treatment-related disease state, distinguishing stable and unstable recovery, to better capture recovery and continuing risks after cirrhosis treatment. This framework could support more consistent research, clinical assessment, and long-term surveillance for patients recover...

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalPortal Hypertension & Cirrhosis·TypeLiterature review·DateOct 14, 2026

The University of Colorado Anschutz receives the largest federal research award in campus history, up to $120 million, to advance new treatments and diagnostics for severe hemorrhage

CU Anschutz will evaluate emerging technologies and therapeutics for severe hemorrhage, including novel blood products and diagnostic technologies. The award aims to improve care for patients experiencing severe bleeding, including trauma patients and those with postpartum hemorrhage.

Insufficient evidence to back medical cannabis for insomnia

A new Cochrane review found insufficient evidence to support the use of medical cannabis for insomnia, with most studies showing little to no improvement in sleep quality and daytime functioning. However, some studies suggested a potential for adverse effects, such as dry mouth and dizziness.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateOct 12, 2026

Digital alerts support timely treatment decisions of critically ill cardiac patients

Researchers found that well-designed digital alerts can assist clinicians in high-pressure situations, prompting them to make recommended treatment decisions and recognize when patients are deteriorating. The studies demonstrated the effectiveness of electronic health record alerts in the emergency department and cardiac intensive care...

SourceMichigan Medicine - University of Michigan·JournalJACC Case Reports·TypeObservational study·DateOct 6, 2026

Alliance Foundation trials and Natera announce AFT-70 navigate: A global, randomized, phase iii trial evaluating genentech’s oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 inhibitor therapy in ER+/HER2− breast canc

The AFT-70 NAVIGATE trial tests a novel molecular residual disease-guided treatment strategy for ER-positive/HER2-negative breast cancer patients. The trial pairs giredestrant with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from treatment escalation with a CDK4/6 inhibitor.

Mount Sinai awarded $2 million to launch international clinical trial on spontaneous coronary artery dissection

Mount Sinai has launched an international clinical trial to determine the optimal treatment for spontaneous coronary artery dissection (SCAD), a sudden tear in the wall of a heart artery that can reduce blood flow and cause an uncommon type of heart attack. The trial, known as SCAD-ALIGN, will compare a moderate antiplatelet strategy o...

Fish may be highly sensitive to antidepressants found in water

Researchers found that fish serotonin transporters, similar to human counterparts, can be highly sensitive to antidepressants found in water, highlighting potential risks to aquatic life. The study suggests prioritizing specific pharmaceuticals in environmental monitoring programs and deriving species-specific risk thresholds.

SourceTokyo University of Science·JournalEnvironmental Science & Technology·TypeExperimental study·DateSep 9, 2026

Mass General Brigham-led trial shows a less-intensive drug combination is more effective in treating AML

A phase 2 clinical trial found that a less-intensive combination of azacitidine and venetoclax was more effective in treating acute myeloid leukemia, with patients tolerating treatment better and spending less time in the hospital. The combination also led to more patients reaching stem cell transplantation.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateSep 2, 2026

Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months

A phase 2 clinical trial found that a monoclonal antibody targeting interleukin-6 achieved sustained reductions in inflammation biomarkers for six months in patients with chronic kidney disease. The therapy, known as pacibekitug, was well-tolerated and showed favorable effects on additional biomarkers associated with cardiovascular risk.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·TypeRandomized controlled/clinical trial·DateAug 29, 2026

Chinese Medical Journal article review explores tryptophan metabolism in female reproduction

This review explores the impact of tryptophan metabolism on female reproductive health, including ovarian function, fertility, and maternal-fetal health. It highlights the therapeutic potential of tryptophan metabolism in treating ovarian diseases and proposes dietary supplementation, modulation of the gut microbiota, and melatonin ant...

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateAug 24, 2026

Alliance reports results from first randomized trial of a radiopharmaceutical in kidney cancer

The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeExperimental study·DateAug 17, 2026